Can higher doses of TB drugs cut treatment time?
NCT ID NCT04694586
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This phase II trial is investigating whether higher doses of two tuberculosis (TB) drugs, rifampicin and pyrazinamide, can safely shorten treatment for people with mild to moderate pulmonary TB. The study compares drug levels and safety of this high-dose regimen against the standard treatment. If successful, this approach could lead to shorter, more effective TB therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- High-dose rifampicin and pyrazinamide
- What this could lead to
- If successful, this could lead to a shorter, more effective treatment for tuberculosis, improving adherence and outcomes.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. High doses of these drugs could increase the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linköping University Hospital
Linköping, S-581 85, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New rapid test could free TB patients from isolation sooner
- New TB cocktail aims to shorten treatment
- AI stethoscope aims to cut unnecessary antibiotics in kids with cough
- Pee test could spot TB patients skipping meds
- Could aspirin or ibuprofen help beat TB faster?
- Exercise program aims to boost lung health in TB survivors